| Chen, Ming-Yuan |
NCT05757479: Steroid-Eluting Stent Implant for the Treatment of Radiation-Related Sinusitis |
|
|
| Recruiting | 3 | 168 | RoW | Steroid-eluting stent implantation, Steroid nasal spray, nasal saline rinses, Nasal irrigation | Sun Yat-sen University, Zhongshan People's Hospital, Guangdong, China, Fifth Affiliated Hospital of Guangzhou Medical University | Radiation-Induced Mucositis | 12/23 | 07/24 | | |
NCT03837808: Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 384 | RoW | Nimotuzumab, Cisplatin | Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong Provincial People's Hospital, First Affiliated Hospital, Sun Yat-Sen University | Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm | 02/24 | 02/24 | | |
NCT04944914: Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 188 | RoW | camrelizumab, stereotactic body radiotherapy, SBRT | Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhongshan People's Hospital, Guangdong, China, Guangdong Provincial People's Hospital | Nasopharyngeal Carcinoma | 06/24 | 06/26 | | |
NCT03840421: GP vs PF as Induction Chemotherapy Combined With CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 3 | 468 | RoW | gemcitabine and cisplatin, gemcitabine and cisplatin (GP), cisplatin and fluorouracil, cisplatin and fluorouracil (PF), IMRT, cisplatin, cisplatin（DDP） | Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong Provincial People's Hospital, First Affiliated Hospital, Sun Yat-Sen University | Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm | 08/26 | 12/28 | | |
NCT04778956: Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 218 | RoW | Toripalimab, PD-1 antibody, salvage surgery | Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Zhongshan People's Hospital, Guangdong, China, Tenth Affiliated Hospital, Sun Yat-sen University | Nasopharyngeal Carcinoma, PD-1, Surgery | 03/25 | 03/33 | | |
NCT04453813: Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 226 | RoW | Toripalimab plus concurrent chemo-radiotherapy, Concurrent chemo-radiotherapy | Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhongshan People's Hospital, Guangdong, China, Yuebei People's Hospital, Wuzhou Red Cross Hospital, Fifth Affiliated Hospital, Sun Yat-Sen University | Nasopharyngeal Carcinoma, Chemotherapy, Radiotherapy, PD-1 Treatment | 07/25 | 07/27 | | |
NCT05854849: Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC |
|
|
| Recruiting | 3 | 244 | RoW | Camrelizumab, Gemcitabine, Cisplatin, Apatinib | Sun Yat-sen University | Nasopharyngeal Carcinoma | 12/25 | 12/27 | | |
NCT04448522: Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 508 | RoW | reduced dosage IMRT, conventional dosage IMRT | Sun Yat-sen University, National Cancer Centre, Singapore, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhongshan People's Hospital, Guangdong, China, Yuebei People's Hospital, Wuzhou Red Cross Hospital | Nasopharyngeal Carcinoma, Radiotherapy, Chemotherapy | 08/26 | 08/28 | | |
NCT04453826: Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 388 | RoW | Camrelizumab plus chemo-radiotherapy, Chemo-radiotherapy alone | Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhongshan People's Hospital, Guangdong, China, Yuebei People's Hospital, Wuzhou Red Cross Hospital, Fifth Affiliated Hospital, Sun Yat-Sen University | Nasopharyngeal Cancer, Chemotherapy, Radiotherapy, PD-1 Therapy | 09/26 | 09/28 | | |
NCT05877872: Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 424 | RoW | Reduced-target resection, Full-target resection, Adjuvant immunotherapy | Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Zhongshan People's Hospital, Guangdong, China, Fifth Affiliated Hospital of Guangzhou Medical University | Nasopharyngeal Carcinoma, De-escaltion Therapy | 03/29 | 03/29 | | |
NCT06092957: Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy |
|
|
| Recruiting | 3 | 504 | RoW | Cisplatin-based induction chemotherapy, Full course of PD-1/PD-L1 blockades, Reduced-dose IMRT, Standard-dose IMRT, Concurrent Chemotherapy | Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong Provincial People's Hospital, Second Affiliated Hospital, Sun Yat-Sen University, The fifth Affiliated Hospital of Guangzhou Medcial University, Zhongshan People's Hospital, Guangdong, China, Hunan Cancer Hospital, Tongji Hospital | Nasopharyngeal Carcinoma, De-escalation Therapy | 10/29 | 10/31 | | |
| Active, not recruiting | 2 | 25 | RoW | Tolipalimab, JS001, Reirradiation | Sun Yat-sen University | Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm | 02/21 | 02/23 | | |
NCT04586088: Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure |
|
|
| Active, not recruiting | 2 | 58 | RoW | Apatinib plus Camrelizumab | Sun Yat-sen University | Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemotherapy Effect, Immunotherapy, Molecular Targeted Therapy | 06/22 | 09/23 | | |
NCT04398056: Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 2 | 22 | RoW | Chemotherapy plus radiotherapy and Toripalimab | Sun Yat-sen University | Nasopharyngeal Carcinoma | 07/22 | 07/24 | | |
NCT05222035: PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure |
|
|
| Recruiting | 2 | 68 | RoW | Camrelizumab, G-CSF | Sun Yat-sen University | PD-1 Inhibitor, G-CSF | 12/22 | 06/23 | | |
NCT05549466: Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC |
|
|
| Recruiting | 2 | 84 | RoW | Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel), Apatinib, Camrelizumab, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel), Chemotherapy (gemcitabine/ capecitabine/ docetaxel) | Sun Yat-sen University | Nasopharyngeal Carcinoma | 09/23 | 09/25 | | |
NCT05724355: CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC |
|
|
| Recruiting | 2 | 32 | RoW | Dalpiciclib Isetionate Tablets, Camrelizumab | Sun Yat-sen University | Nasopharyngeal Carcinoma | 10/23 | 10/24 | | |
NCT05431764: Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 38 | RoW | Camrelizumab, gemcitabin, cisplatin, PD-1 inhibitor, Stereotactic Body Radiotherapy, Intensity modulated-radiotherapy, SBRT, IMRT | Sun Yat-sen University | Nasopharyngeal Carcinoma | 06/25 | 06/26 | | |
NCT05341193: PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 1/2 | 32 | RoW | Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab, Bevacizumab+Toripalimab+gemcitabine, adjuvant with Toripalimab | Sun Yat-sen University, The First Hospital of Nanchang | Nasopharyngeal Carcinoma | 04/23 | 12/25 | | |
NCT04073784: Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma. |
|
|
| Active, not recruiting | 1 | 41 | RoW | Gemcitabine combined with Aptinib and Toripalimab | Sun Yat-sen University | Nasopharyngeal Carcinoma | 04/22 | 04/24 | | |
NCT05222009: G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 1 | 25 | RoW | PEG-rhG-CSF | Sun Yat-sen University | Granulocyte Colony-Stimulating Factor, PD-1 Inhibitor | 11/22 | 08/23 | | |
NCT02456506: Hyperfractionated Intensity-modulated Radiotherapy (IMRT) Versus Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma. |
|
|
| Active, not recruiting | N/A | 142 | RoW | Hyperfractionated IMRT, Conventional Fraction IMRT | Sun Yat-sen University | Nasopharyngeal Neoplasms, Mortality, Quality of Life, Complications | 12/22 | 03/23 | | |
NCT05037357: Verification of Harmonization of Plasma Epstein-Barr Virus DNA Measurements |
|
|
| Recruiting | N/A | 370 | RoW | Plasma EBV DNA qPCR test | Sun Yat-sen University, Wuzhou Red Cross Hospital, Zhongshan People's Hospital, Guangdong, China | Nasopharyngeal Carcinoma | 12/22 | 06/24 | | |
NCT05228093: A Randomized Controlled Clinical Trial of Surgery Versus Conservative Treatment for Mild and Moderate-grade Nasopharyngeal Necrosis |
|
|
| Recruiting | N/A | 216 | RoW | Curative-intent endoscopic necrectomy followed by reconstruction using the posterior pedicle nasal septum and floor mucoperiosteum flap, Conservative treatment | Sun Yat-sen University | Nasopharyngeal Carcinoma, Postradiation, Necrosis, Endoscopy Surgery, Conservative Treatment | 10/23 | 10/24 | | |
NCT04425265: Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma |
|
|
| Recruiting | N/A | 248 | RoW | Plasma radiofrequency ablation, Electrocautery block resection | Sun Yat-sen University | Surgery, Recurrent Nasopharyngeal Carcinoma | 06/24 | 05/25 | | |
NCT05352321: Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma |
|
|
| Recruiting | N/A | 264 | RoW | Gemcitabine, Cisplatin, regular intensity-modulated radiotherapy, surgery, Endoscopic nasopharyngectomy, Retropharyngeal lymphadenectomy, Neck lymph node dissection, Target-reduction intensity-modulated radiotherapy | Sun Yat-sen University | Nasopharyngeal Carcinoma | 06/25 | 06/28 | | |
NCT05447169: Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening |
|
|
| Recruiting | N/A | 11625 | RoW | EBV antibodies test, EBV DNA test | Sun Yat-sen University, Wuzhou Red Cross Hospital, Zhongshan People's Hospital, Guangdong, China, Hunan Cancer Hospital, The Third Affiliated Hospital of Nanchang University, First People's Hospital of Foshan, Yuebei People's Hospital, Xiangya Hospital of Central South University, Changsha Central Hospital | Nasopharyngeal Carcinoma | 07/25 | 07/30 | | |
NCT03353467: Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients |
|
|
| Recruiting | N/A | 228 | RoW | Endoscopic surgery, Intensity-modulated radiotherapy | Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, First People's Hospital of Foshan, Zhongshan People's Hospital, Guangdong, China, People's Hospital of Guangxi | Nasopharyngeal Carcinoma, Endoscopic Surgery, Primary Napharyngeal Carcinama, Stage I Nasopharyngeal Cancer | 10/25 | 10/28 | | |
